Skip to content
To see all protocols that comply with the WHO Essential Medicine List
Cancer Institute NSW sites
eviQ Education
Learning resources for cancer staff
Cancer Institute NSW
NSW cancer control agency
Patient Information
Practical advice about cancer
Canrefer
Find a cancer specialist
BreastScreen NSW
Detect breast cancer early
Cervical Screening NSW
Cervical Screening NSW
iCanQuit
Learn how to quit smoking
Log in
Register
Search
Search
Log in
Register
Search
Main menu Toggle menu collaspe
Search eviQ
Close
Search
Search
Home
Home
Cancer genetics
Adult
Genetic testing for heritable pathogenic variants
Genetic testing using cancer gene panels
Risk management
Paediatric
Genetic testing for heritable pathogenic variants
Genetic testing using cancer gene panels
Risk management
Referral guidelines
Consumer information
Resources
Haematology and BMT
Leukaemias
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Acute promyelocytic leukaemia
Chronic lymphocytic leukaemia
Chronic myeloid leukaemia
Hairy cell leukaemia
Myelodysplastic disorders
Lymphoma
Non-Hodgkin lymphoma
Hodgkin lymphoma
Burkitt lymphoma
Mantle cell lymphoma
Primary CNS lymphoma
Waldenstrom macroglobulinaemia
Multiple myeloma
Blood and marrow transplant
Mobilisation
Allogeneic
Autologous
Cellular therapies
Medical oncology
Breast
Adjuvant/neoadjuvant
Metastatic
Colorectal
Adjuvant and neoadjuvant
Metastatic
Anal
Rectal
Gynaecological
Cervical
Endometrial
Gestational trophoblastic disease
Ovarian
Vulval
Head and neck
Definitive chemoradiation
Induction chemotherapy
Nasopharyngeal
Post operative chemoradiation
Recurrent or metastatic
Salivary gland
Thyroid
Neurological
Glioma
Respiratory
Mesothelioma
Non small cell lung cancer - Adjuvant/neoadjuvant
Non small cell lung cancer - Advanced/metastatic
Small cell lung cancer
Sarcoma
Soft tissue sarcoma
Bone sarcoma
Skin
Melanoma adjuvant
Melanoma metastatic
Non-melanoma
Upper gastrointestinal
Gastric and oesophageal adjuvant and neoadjuvant
Gastric and oesophageal metastatic
Gastrointestinal stromal cell tumours
Hepatic
Neuroendocrine
Pancreas and biliary
Urogenital
Adrenocortical
Bladder and Urothelial
Prostate
Renal
Testicular
Rare cancers
Colorectal
Gynaecological
Head and neck
Melanoma
Neurological
Respiratory
Sarcoma
Upper gastrointestinal
Urogenital
Radiation oncology
Breast
Colorectal
Gynaecological
Haematology
Head and neck
Neurological
Palliative
Respiratory
Upper gastrointestinal
Urogenital
Bladder
Prostate
Skin
Stereotactic
Clinical resources
eviQ calculators
Aboriginal health workers
ADDIKD guideline
Administration of anti-cancer drugs
Assessment tools
BMT & cellular therapies
Central venous access devices (CVADs)
Day of Treatment Assessment
Extravasation
Pumps
Health professional fact sheets
Oncological emergencies
Radiation oncology
Assessment tools
Cardiac implantable electronic devices
Contrast administration
Health professional fact sheets
Radiation-induced dermatitis
Side effect and toxicity management
Side effect and toxicity management
Cardiovascular
Gastrointestinal
General
Genitourinary
Gynaecological
Haematological
Hair, skin and nails
Immunological
Neurological and sensory
Oropharyngeal
Prophylaxis and treatment
Reproductive
Respiratory
Telephone triage toolkit
COVID-19
Patients and carers
Anticancer drug treatments
Radiation therapy treatments
Cancer genetics information sheets
Patient information sheets
At home
Cancer type specifics
Complementary and alternative medicines
Eating and drinking
Fertility, sex, pregnancy and breastfeeding
Treating cancer with medicines
How you have anticancer medicine treatment
Treating cancer with radiation therapy
How you have radiation therapy treatment
Managing side effects
Vaccinations
Your family and friends
Patient information in other languages
عربى (Arabic)
简 (Simplified Chinese)
繁 (Traditional Chinese)
Français (French)
Ελληνικά (Greek)
Italiano (Italian)
한국어 (Korean)
Español (Spanish)
Tiếng Việt (Vietnamese)
Македонски (Macedonian)
ไทย (Thai)
Patient information videos
Cancer Institute NSW sites
eviQ Education
Learning resources for cancer staff
Cancer Institute NSW
NSW cancer control agency
Patient Information
Practical advice about cancer
Canrefer
Find a cancer specialist
BreastScreen NSW
Detect breast cancer early
Cervical Screening NSW
Cervical Screening NSW
iCanQuit
Learn how to quit smoking
Home
181 results for 'lung'
Search
Protocols (94)
Clinical Resources (1)
Patients and Carers (86)
No results found.
Cancer genetics > Consumer information
Facts for people and families with a faulty TP53 gene (Li-Fraumeni syndrome)
Facts for people and families with Birt-Hogg-Dubé syndrome
Facts for people and families with Multiple Endocrine Neoplasia type 1
Cancer genetics > Paediatric > Risk management
RB1 (non-retinoblastoma cancer risk) – risk management
Medical oncology > Respiratory > Mesothelioma
Mesothelioma cARBOplatin and pemetrexed
Mesothelioma cARBOplatin pemetrexed and beVACizumab
Mesothelioma ciSplatin and pemetrexed
Mesothelioma ciSplatin pemetrexed and beVACizumab
Mesothelioma ipilimumab and nivolumab (flat dosing)
Mesothelioma vinORELBine
Mesothelioma ipilimumab and nivolumab (weight based dosing) SUPERSEDED
Medical oncology > Respiratory > Non small cell lung cancer - Adjuvant/neoadjuvant
Non small cell lung cancer adjuvant atezolizumab
Non small cell lung cancer adjuvant ciSplatin and pemetrexed
Non small cell lung cancer adjuvant ciSplatin and vinORELBine
Non small cell lung cancer adjuvant osimertinib
Non small cell lung cancer neoadjuvant cARBOplatin, PACLitaxel and nivolumab
Non small cell lung cancer neoadjuvant ciSplatin, gemcitabine and nivolumab
Non small cell lung cancer neoadjuvant ciSplatin, pemetrexed and nivolumab
Non small cell lung cancer superior sulcus (Pancoast) ciSplatin and etoposide chemoradiation pre-operative
Medical oncology > Respiratory > Non small cell lung cancer - Advanced/metastatic
Advanced or metastatic nivolumab (flat dosing)
Advanced, metastatic or recurrent pembrolizumab
Locally advanced or metastatic cemiplimab
Non small cell lung cancer locally advanced definitive cARBOplatin and PACLitaxel chemoradiation
Non small cell lung cancer locally advanced definitive ciSplatin and etoposide chemoradiation
Non small cell lung cancer locally advanced durvalumab (flat dosing) (following chemoradiation)
Non small cell lung cancer locally advanced durvalumab (weight based dosing) (following chemoradiation)
Non small cell lung cancer locally advanced or metastatic alectinib
Non small cell lung cancer locally advanced or metastatic atezolizumab
Non small cell lung cancer locally advanced or metastatic brigatinib
Non small cell lung cancer locally advanced or metastatic cARBOplatin and DOCEtaxel
Non small cell lung cancer locally advanced or metastatic cARBOplatin and gemcitabine
Non small cell lung cancer locally advanced or metastatic cARBOplatin and PACLitaxel
Non small cell lung cancer locally advanced or metastatic cARBOplatin and pemetrexed
Non small cell lung cancer locally advanced or metastatic cARBOplatin and weekly PACLitaxel
Non small cell lung cancer locally advanced or metastatic ciSplatin and gemcitabine
Non small cell lung cancer locally advanced or metastatic ciSplatin and pemetrexed
Non small cell lung cancer locally advanced or metastatic entrectinib
Non small cell lung cancer locally advanced or metastatic lorlatinib
Non small cell lung cancer locally advanced or metastatic osimertinib
Non small cell lung cancer locally advanced or metastatic sotorasib
Non small cell lung cancer locally advanced or metastatic tepotinib
Non small cell lung cancer metastatic aFATinib
Non small cell lung cancer metastatic cARBOplatin PACLitaxel atezolizumab and beVACizumab
Non small cell lung cancer metastatic cARBOplatin PACLitaxel ipilimumab and nivolumab
Non small cell lung cancer metastatic cARBOplatin, PACLitaxel and pembrolizumab
Non small cell lung cancer metastatic cARBOplatin, pemetrexed and pembrolizumab
Non small cell lung cancer metastatic ciSplatin, pemetrexed and pembrolizumab
Non small cell lung cancer metastatic DOCEtaxel three weekly
Non small cell lung cancer metastatic gemcitabine
Non small cell lung cancer metastatic pemetrexed
Non small cell lung cancer metastatic vinORELBine (intravenous)
Non small cell lung cancer metastatic vinORELBine (oral)
Advanced or metastatic nivolumab (weight based dosing) SUPERSEDED
Non small cell lung cancer locally advanced or metastatic cARBOplatin and vinORELBine SUPERSEDED
Non small cell lung cancer locally advanced or metastatic ceritinib SUPERSEDED
Non small cell lung cancer locally advanced or metastatic ciSplatin and vinORELBine SUPERSEDED
Non small cell lung cancer locally advanced or metastatic crizotinib SUPERSEDED
Non small cell lung cancer metastatic DOCEtaxel weekly SUPERSEDED
Non small cell lung cancer metastatic erlotinib SUPERSEDED
Non small cell lung cancer metastatic gefitinib SUPERSEDED
Non small cell lung cancer metastatic cARBOplatin and gemcitabine (day 8 cARBOplatin) DISCONTINUED
Non small cell lung cancer metastatic cISplatin and DOCEtaxel DISCONTINUED
Non small cell lung cancer metastatic ciSplatin and gemcitabine (day 8 ciSplatin) DISCONTINUED
Medical oncology > Respiratory > Small cell lung cancer
Small cell lung cancer advanced topotecan (modified)
Small cell lung cancer extensive disease cARBOplatin and etoposide
Small cell lung cancer extensive disease cARBOplatin and oral etoposide
Small cell lung cancer extensive disease cARBOplatin etoposide and atezolizumab
Small cell lung cancer extensive disease cARBOplatin etoposide and durvalumab
Small cell lung cancer extensive disease CAV (CYCLOPHOSPHamide DOXOrubicin vinCRISTine)
Small cell lung cancer extensive disease ciSplatin and irinotecan
Small cell lung cancer limited disease cARBOplatin and etoposide
Small cell lung cancer limited disease ciSplatin and etoposide
Small cell lung cancer limited disease ciSplatin and etoposide chemoradiation
Radiation oncology > Palliative
Palliative respiratory superior vena cava obstruction EBRT
Respiratory lung oligometastases definitive stereotactic EBRT peripheral tumours
Respiratory lung primary palliative EBRT
Radiation oncology > Respiratory
Palliative respiratory superior vena cava obstruction EBRT
Respiratory lung oligometastases definitive stereotactic EBRT peripheral tumours
Respiratory lung primary palliative EBRT
Respiratory non-small cell lung cancer adjuvant EBRT post-operative
Respiratory non-small cell lung cancer definitive EBRT hypofractionation
Respiratory non-small cell lung cancer definitive EBRT with or without chemotherapy
Respiratory non-small cell lung cancer definitive stereotactic EBRT central tumours
Respiratory non-small cell lung cancer definitive stereotactic EBRT peripheral tumours
Respiratory non-small cell lung cancer superior sulcus (Pancoast) neoadjuvant EBRT chemoradiation
Respiratory small cell lung cancer adjuvant prophylactic cranial irradiation EBRT extensive-stage
Respiratory small cell lung cancer adjuvant prophylactic cranial irradiation EBRT limited-stage
Respiratory small cell lung cancer consolidative EBRT
Respiratory small cell lung cancer thoracic EBRT with or without chemotherapy
Respiratory small cell lung cancer definitive EBRT DISCONTINUED
Respiratory small cell lung cancer EBRT hyperfractionation DISCONTINUED
Radiation oncology > Stereotactic
Respiratory lung oligometastases definitive stereotactic EBRT peripheral tumours
Respiratory non-small cell lung cancer definitive stereotactic EBRT central tumours
Respiratory non-small cell lung cancer definitive stereotactic EBRT peripheral tumours
No results found.
Clinical resources > Side effect and toxicity management > Respiratory
Pulmonary toxicity associated with anti-cancer agents
No results found.
Medical oncology > Respiratory > Mesothelioma
Patient information - Mesothelioma - Carboplatin and pemetrexed
Patient information - Mesothelioma - Carboplatin, pemetrexed and bevacizumab
Patient information - Mesothelioma - Cisplatin and pemetrexed
Patient information - Mesothelioma - Cisplatin, pemetrexed and bevacizumab
Patient information - Mesothelioma - Ipilimumab and nivolumab - flat dosing
Patient information - Mesothelioma - Vinorelbine
Patient information - Mesothelioma - Ipilimumab and nivolumab - weight based dosing
Medical oncology > Respiratory > Non small cell lung cancer - Adjuvant/neoadjuvant
Patient information - Lung cancer - Cisplatin and etoposide with radiation therapy superior sulcus (Pancoast)
Patient information - Lung cancer adjuvant - Atezolizumab
Patient information - Lung cancer adjuvant - Cisplatin and pemetrexed
Patient information - Lung cancer adjuvant - Cisplatin and vinorelbine
Patient information - Lung cancer adjuvant - Osimertinib
Patient information - Lung cancer neoadjuvant - Carboplatin, paclitaxel and nivolumab
Patient information - Lung cancer neoadjuvant - Cisplatin, gemcitabine and nivolumab
Patient information - Lung cancer neoadjuvant - Cisplatin, pemetrexed and nivolumab
Medical oncology > Respiratory > Non small cell lung cancer - Advanced/metastatic
Patient information - Advanced or metastatic - Nivolumab - flat dosing
Patient information - Advanced, metastatic or recurrent - Pembrolizumab
Patient information - Locally advanced or metastatic - Cemiplimab
Patient information - Lung cancer advanced - Carboplatin and paclitaxel with radiation therapy
Patient information - Lung cancer advanced or metastatic - Alectinib
Patient information - Lung cancer advanced or metastatic - Carboplatin and pemetrexed
Patient information - Lung cancer advanced or metastatic - Osimertinib
Patient information - Lung cancer advanced or metastatic - Sotorasib
Patient information - Lung cancer locally advanced - Cisplatin and etoposide with radiation therapy
Patient information - Lung cancer locally advanced - Durvalumab - flat dosing
Patient information - Lung cancer locally advanced - Durvalumab - weight based dosing
Patient information - Lung cancer locally advanced or metastatic - Atezolizumab
Patient information - Lung cancer locally advanced or metastatic - Brigatinib
Patient information - Lung cancer locally advanced or metastatic - Carboplatin and docetaxel
Patient information - Lung cancer locally advanced or metastatic - Carboplatin and gemcitabine
Patient information - Lung cancer locally advanced or metastatic - Carboplatin and paclitaxel
Patient information - Lung cancer locally advanced or metastatic - Carboplatin and weekly paclitaxel
Patient information - Lung cancer locally advanced or metastatic - Cisplatin and gemcitabine
Patient information - Lung cancer locally advanced or metastatic - Cisplatin and pemetrexed
Patient information - Lung cancer locally advanced or metastatic - Entrectinib
Patient information - Lung cancer locally advanced or metastatic - Lorlatinib
Patient information - Lung cancer locally advanced or metastatic - Tepotinib
Patient information - Lung cancer metastatic - Afatinib
Patient information - Lung cancer metastatic - Carboplatin, paclitaxel and pembrolizumab
Patient information - Lung cancer metastatic - Carboplatin, paclitaxel, atezolizumab and bevacizumab
Patient information - Lung cancer metastatic - Carboplatin, paclitaxel, ipilimumab and nivolumab
Patient information - Lung cancer metastatic - Carboplatin, pemetrexed and pembrolizumab
Patient information - Lung cancer metastatic - Cisplatin, pemetrexed and pembrolizumab
Patient information - Lung cancer metastatic - Docetaxel
Patient information - Lung cancer metastatic - Gemcitabine
Patient information - Lung cancer metastatic - Pemetrexed
Patient information - Lung cancer metastatic - Vinorelbine (intravenous)
Patient information - Lung cancer metastatic - Vinorelbine (oral)
Patient information - Advanced or metastatic - Nivolumab - weight based dosing
Patient information - Lung cancer advanced or metastatic - Ceritinib
Patient information - Lung cancer locally advanced or metastatic - Carboplatin and vinorelbine
Patient information - Lung cancer locally advanced or metastatic - Cisplatin and vinorelbine
Patient information - Lung cancer metastatic - Crizotinib
Patient information - Lung cancer metastatic - Docetaxel weekly
Patient information - Lung cancer metastatic - Erlotinib
Patient information - Lung cancer metastatic - Gefitinib
Medical oncology > Respiratory > Small cell lung cancer
Patient information - Lung cancer advanced - Topotecan
Patient information - Lung cancer extensive disease - Carboplatin and etoposide
Patient information - Lung cancer extensive disease - Carboplatin and oral etoposide
Patient information - Lung cancer extensive disease - Carboplatin, etoposide and atezolizumab
Patient information - Lung cancer extensive disease - Carboplatin, etoposide and durvalumab
Patient information - Lung cancer extensive disease - CAV (cyclophosphamide, doxorubicin, vincristine)
Patient information - Lung cancer extensive disease - Cisplatin and irinotecan
Patient information - Lung cancer limited disease - Carboplatin and etoposide
Patient information - Lung cancer limited disease - Cisplatin and etoposide
Patient information - Lung cancer limited disease - Cisplatin and etoposide with radiation therapy
Patients and carers > Patient information sheets > Managing side effects
Lung damage from bleomycin
Radiation oncology > Palliative
Patient information - Lung cancer - External Beam Radiation Therapy (EBRT) - palliative
Patient information - Metastatic - Lung oligometastases - Stereotactic ablative radiation therapy (SABR)
Patient information - Superior vena cava obstruction (SVCO) - External Beam Radiation Therapy (EBRT)
Radiation oncology > Respiratory
Patient information - Brain irradiation for small cell lung cancer - External Beam Radiation Therapy (EBRT) - extensive stage
Patient information - Brain irradiation for small cell lung cancer - External Beam Radiation Therapy (EBRT) - limited stage
Patient information - Lung cancer - External beam radiation therapy - non-small cell lung cancer (hypofractionation)
Patient information - Lung cancer - External Beam Radiation Therapy (EBRT) - non small cell lung cancer (NSCLC)
Patient information - Lung cancer - External Beam Radiation Therapy (EBRT) - palliative
Patient information - Lung cancer - External Beam Radiation Therapy (EBRT) - post operative
Patient information - Lung cancer - External Beam Radiation Therapy (EBRT) - small cell lung cancer (SCLC)
Patient information - Lung cancer - External Beam Radiation Therapy (EBRT) - superior sulcus/Pancoast
Patient information - Lung cancer - Non small cell (central) - Stereotactic ablative radiation therapy (SABR)
Patient information - Lung cancer - Non small cell (peripheral) - Stereotactic ablative radiation therapy (SABR)
Patient information - Lung cancer - Small cell lung cancer (SCLC) - External Beam Radiation Therapy (EBRT)
Patient information - Lung oligometastases - Stereotactic ablative radiation therapy (SABR)
Patient information - Superior vena cava obstruction (SVCO) - External Beam Radiation Therapy (EBRT)
Radiation oncology > Stereotactic
Patient information - Lung cancer - Non small cell (central) - Stereotactic ablative radiation therapy (SABR)
Patient information - Lung cancer - Non small cell (peripheral) - Stereotactic ablative radiation therapy (SABR)
Patient information - Lung oligometastases - Stereotactic ablative radiation therapy (SABR)
Title
Content